Anthera Pharma (ANTH) PT Lowered to $1.75 at Jefferies Following 2Q
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Anthera Announces FDA Orphan Drug Designation for Blisibimod for the Treatment of IgA Nephropathy
August 9, 2017 4:00 PM EDTHAYWARD, Calif., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals (Nasdaq: ANTH) today announced that blisibimod has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of Immunoglobulin A nephropathy (IgAN). Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including IgAN, systemic lupus erythematosus, and others.
We are pleased by the FDAs decision to designate blisibimod with orphan drug designation, said Craig Thompson, Chief Executive Officer of Anthera. There remains a very... More
Anthera Pharmaceuticals Provides Business Update and Reports 2017 Second Quarter Financial Results
August 9, 2017 8:30 AM EDTRESULT, pivotal Phase 3 study of Sollpura began screening patients in the U.S. and EuropeRESULT study approved by the Cystic Fibrosis Foundation Therapeutics Development NetworkBRIGHT, Phase 2 study of blisibimod in IgA Nephropathy remains on track to report topline data in Q3Executed equity purchase agreement for the sale of up to $10 million in common stock at the Companys discretionReceived extension from Nasdaq to regain listing compliance
HAYWARD, Calif., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today provided a business update and reported financial results for the... More
